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Summary
Factor VIII activity (factor VIII:C) levels >150 lU/dl are associated
with a 5- to 6-fold increased risk of venous thrombosis compared to lev-
els <100 lU/dl, and fibrinogen levels >5.0 g/l increase the thrombosis
risk 4-fold. These high levels are present in 25% resp. 3% of the patients
with a first episode of venous thrombosis. These findings were based on
measurements after the thrombotic event, so the factor VIII and fibrino-
gen levels in thrombosis patients may have been influenced by acute
phase reactions or ongoing inflammatory responses. In the present
study we measured plasma C-reactive protein (CRP) äs a sensitive
marker of an acute phase reaction in 474 thrombosis patients and 474
age- and sex-matched healthy controls, that were pari of the Leiden
Thrombophilia Study (LETS). Mean and median CRP levels were
higher in thrombosis patients than in the controls, suggesting inflamma-
tion in some patients. CRP affected both factor VIII and fibrinogen
levels, in patients and controls alike. After adjustment for the effect of
CRP, high factor VIII: C levels still increased the thrombosis risk 6-fold
and high fibrinogen levels 4-fold, which is for both very similar to the
risk before correction for CRP levels. These results show that although
systemic inflammation may be present in some of the patients, elevated
levels of factor VIII:C and fibrinogen were in general not caused by
acute phase reactions. This further supports a causal relationship
between both high factor VIII:C and fibrinogen levels and venous
thrombosis.
introduction
Factor VIII procoagulant activity (factor VIII:C) levels >150 lU/dl
are associated with a 5- to 6-fold increased risk of venous thrombosis
when compared to levels below 100 ITJ'/dl (1). The prevalence of elevat-
ed factor VIII levels is high: 25% of the patients with a first episode of
venous thrombosis and 11% of the healthy population (1). Furthermore,
we and others have shown that elevated factor VIILC levels, äs meas-
ured with a one-stage assay, are highly correlated with factor VIII anti-
gen (factor VIII:Ag) levels. This suggests that the observed elevation of
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Fig. l Hypothetical pathways for the relation between elevated factor VK
levels and venous thrombosis
factor VIII:C levels is not the result of activation of the coagulation
System during the blood collection procedure (2,3). Indeed, also factor
VIII:Ag levels >150 lU/dl were found to be associated with a 5-fold in-
creased risk of venous thrombosis (2).
Fibrinogen has also been associated with an increased risk for
thrombosis (4). We previously reported that fibrinogen levels >5.0 g/l
increase the risk 3- to 4-fold, compared to the reference category (<3.0g/l).
Such high levels were present in 3% of the thrombosis patients and 1%
of the controls.
The conclusions that elevated factor VIII and fibrinogen levels are
associated with an increased thrombosis risk, are based on measure-
ments in patients after the thrombotic event; it can therefore not be ex-
cluded that these measurements were influenced by ongoing inflamma-
tory processes triggered by the thrombosis itself or its sequelae. So,
elevated factor VIII and fibrinogen levels may either be the cause
of thrombosis (Fig. l A), or the consequence of chronic inflammatory
reactions that follow the thrombosis (Fig. 1B).
In the present study we investigated whether factor VIILC and fi-
brinogen levels in thrombosis patients are associated with C-reactive
protein levels, which is a sensitive marker for acute phase processes
underlying inflammation (5). We measured these levels in 474 throm-




The patients and controls induded in this study came from a population-
based case-control study on venous thrombosis, the Leiden Thrombophilia
Study (LETS^(l). This study includes 474 unselected consecuüve out-patients,
younger than 70 years who were referred for anticoagulant treatment after
a first, objectively confirmed episode of deep-vein thrombosis and who <Bd
not have an underlying malignancy. The median time between the occurrence
of the deep-vein thrombosis and blood collection was 18 months (ränge,
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Table l Mean and median plasma C-reactive protein levels in thrombosis














6-48 months). Each thrombosis patient provided bis or her own sex- and age-
matched healthy control subject according to predefmed cnteria (6). The njean
age for patients and controls was 47 years (ränge 16 to 70 years for patients,
16 to 73 for controls).
Blood Collection and Plasma Assays
Blood was collected in tubes containing 0.106 mmol/1 trisodium citrate.
Plasma was prepared by centrifugation for 10 min at 2000 X g at room temper-
ature and stored at --70° C. Factor VIII:C levels were measured by a one-stage
clotting assay (1). The fibrinogen concentration was determined according to
the von Clauss method using Dade® thrombin (Baxter, Miami, Fl). C-reactive
protein was measured by a Sandwich enzyme immunoassay (Kordia, Leiden,
The Netherlands), based on two polyclonal rabbit antibodies against CRP. The
lower detection level of this lest is 0.05 mg/1, so it is sufficiently sensitive to
measure CRP levels within the normal ränge (0.2-6.0 mg/1). Pooled normal
plasma was used äs a reference.
Statistical Analysis
For calculations of the mean CRP level, C-reactive protein values were log-
arithmically transformed, because the distribution of the values was skewed.
Geometrie mean concentrations were calculated for both patients and controls.
The non-transformed CRP levels were entered in the regression model, because
logarithmic transformation led to the same results. Factor VIII:C levels were
stratified into quartiles based on patient and control values (1), fibrinogen into
four groups, based on an increase of l g/l in the plasma fibrinogen level (4), to
facilitate comparisons with our earlier reports. We calculated risks relative to
the group with the lowest level. As covariates we included smoking and body
mass index. Multivariate analysis was performed with a conditional logistic
model, that calculated matched odds ratios (OR) and 95% confidence intervals
(95% CI) äs a measure for the relative risk.
Results
Among the controls, mean CRP level was 1.12 mg/1, with a ränge
between 0.06 and 58 mg/1. Smoking, age, and body mass index (BMI)
were associated with the CRP level: smokers (n = 241) had higher lev-
els than nonsmokers (n = 607) (1.30 vs. 1.03 mg/1). An increase in BMI
of l kg/m2 increased the CRP level by 0.18 mg/1. For every successive
10 years of age, the mean CRP level increased 0.7 mg/1. Plasma
CRP levels were the same in men (1.31 mg/1, n = 404) and women
(1.28 mg/1, n = 544).
WiTcompared the CRP values in thrombosis patients and controls.
Table l.shows that both the mean and median level of C-reactive pro-
tein were higher in patients (1.49 mg/1,95% CI, 1.32-1.68) than in controls
(1.12 mg/1,95% CI, 1.00-1.25). This difference was not affected by body
mass index or smoking Status. Fifty-three patients (11%) had plasma
CRP levels above the 95th percentile of the control values (9.75 mg/dl).
When the analysis was restricted to CRP levels below 9.75 mg/dl, the
difference in CRP levels between patients and controls disappeared.
Next, we analyzed the thrombosis risk of both factor VIII:C and fi-
brinogen after adjusting for CRP. We adjusted for CRP first by entering
factor VIII, fibrinogen and CRP äs continuous variable in the logistic
regression model, and second äs categorized variables. As unadjusted
continuous variable, the odds ratio for a 10 lU/dl increase in factor
VIII:C level was 1.19 (95% CI, 1.14-1.23) and this risk remained the
same after adjustment for CRP levels (OR 1.19, 95% CI, 1.14-1.23).
Table 2 shows that after categorization, factor VIII:C levels >150 lU/dl
gave a nearly sevenfold increased risk of venous thrombosis äs com-
pared with the reference category (factor VIII:C <100 lU/dl). After ad-
justment for categorized CRP levels, the risk of elevated factor VIII:C
levels remained virtually unaffected. The adjusted odds ratio of factor
VIII:C levels >150 lU/dl was 6.7 (95% CI, 4.0-11.2). The thrombosis
risk of fibrinogen increased by 1.38 (95% CI, 1.16-1.64) for every g/l
increase. Adjustment for CRP levels did not change this risk estimate
materially (OR 1.28, 95% CI, 1.05-1.56). Also the thrombosis risk of
elevated fibrinogen levels remained the same after adjustment for CRP
levels: subjects with a fibrinogen level above 5 g/l had a fourfold high-
er risk than those in the reference category (<3.0 g/l) (Table 2).
We investigated the influence of CRP on factor VIII:C and fibrino-
gen levels by linear regression. The influence of CRP (mg/1) on factor
VIII:C levels (lU/dl) was weak, without a clear difference between
thrombosis patients and controls (regression coefficient patients 1.49,
95% CI, 0.98-2.00; regression coefficient controls 1.22,95% CI, 0.67
to l .77). For fibrinogen, no differences in the influence of CRP between
patients and controls were found. The regression coefficient was
0.05 (95% CI, 0.04-0.06) in patients and 0.07 (95% CI, 0.05-0.07) in
controls.
Because in this study all samples were drawn after the thrombotic
event, we investigated whether elevated CRP levels in the patients
might have been caused by the thrombotic event. If a relation exists
between the thrombosis and a subsequent inflammatory response, one
Table 2 Unadjusted and adjusted thrombosis
risk for factor VIII:C and fibrinogen levels
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Fig. 2 Mean C-reactive protein levels (± SE) in thrombosis patients (black
bars) and in controls (white bars) at different tirae-intervals between the throm-
botic event and the time of venepuncture
would expect an inverse relationship between CRP levels and the time
between the thrombotic event and the venepuncture. Fig. 2 shows the
mean CRP levels for four different post-thrombosis intervals, here de-
fined äs the time between the occurrence of the thrombosis and the col-
lection of the plasma samples. We found no association between CRP
levels and post-thrombosis intervals, although the first interval, <1 year
after the thrombosis, seemed to have a higher CRP level (1.82 mg/1)
than those collected in the other intervals. The mean CRP levels were
always higher in patients than in controls.
Discussion
Elevated factor VIII levels substantially increase the risk of venous
thrombosis (1). Blood group and von Willebrand factor (vWF) are ira-
portant determinants of the factor VIII level in plasma, and factor VIII
appears to be the final effector in promoting deep-vein thrombosis.
High levels of fibrinogen are also associated with an increased risk of
thrombosis (4). We measured an established acute phase marker, C-re-
active protein (5), to assess if these associations might be the result of
acute phase reactions. Although the mean CRP levels were higher in
thrombosis patients than in controls, the effect of CRP levels on factor
VIII and fibrinogen levels did not differ between patients and controls.
The thrombosis risk of both elevated factor VIILC and fibrinogen re-
mained virtually unchanged after adjustment for CRP levels. We there-
fore conclude that the previously reported associations between high
levels of factor VIII and fibrinogen are not caused by post-thrombotic
inflammatory responses.
In our patient population, most CRP values feil within the normal
ränge, indicating that overall an acute-phase response was absent (7,8).
The minimum interval between the thrombotic event and the time of the
venepuncture was six months. Comparing four different time-intervals,
we found no clear relation between the average CRP level and the post-
thrombotic time-interval. Mean CRP levels were higher in thrombosis
patients than in controls, independent of the time elapsed since the
thrombosis. This difference was the result of the higher number of pa-
tients with elevated CRP levels: 11% of the patients had CRP levels
above the 95th percentile of the control value (9.75 mg/1). This Unding
suggests that systemic inflammation, although infrequent, was more
prominent among the patients than among the controls. CRP levels may
have been affected by the post-thrombotic syndrome, a disease that
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occurs in about 30-50% of the thrombosis patients (9,10). In addition
elevated CRP levels may be a risk factor itself for venous thrombosis'
In the latter case, elevated CRP levels were already present before ihr
occurrence of the thrombosis. This possibility is supported by the eifert
of CRP on tissue factor expression in monocytes (11), which at least m
vitro might result in a procoagulant state, The only prospective stud\
that studied elevated CRP levels and venous thrombosis, the Physician's
Health Study (12), found no relation. It is unclear whether the elevated
CRP levels in our patients are persistent, and what the clinical conse-
quences of these elevations are.
O'Donnell et al. found no clear relation between high factor VIIl'C
levels and C-reactive protein in thrombosis patients (3). Our results
agree with, and extend these observations, because we analyzed the in-
fluence of CRP on factor VIII and fibrinogen comparing patients and
controls.
Theoretically, there are two approaches to assess the relation
between high factor VIII and fibrinogen levels and the risk of venous
thrombosis, when there is concern that the thrombosis itself affected the
clotting factor levels, e.g., by chronic inflammatory responses. The first
is to measure and to adjust for systemic inflammation, in this case by
CRP. When high factor VIII and fibrinogen levels in thrombosis pa-
tients are the result of inflammation, no effect will be visible condition-
al on the CRP levels and correction will lead to attenuation of the ob-
served thrombosis risk. We showed that this is not the case. A second
approach is to assess the effect of genetic determinants of clotting fac-
tor levels, since they, obviously, cannot be affected by the occurrence
of thrombosis (13). Our previous observation that blood group, which
acts via vWF, affects the factor VIII level (1), can be viewed äs such an
analysis, i.e., showing an unconfounded effect of factor VIII levels
which is not brought about by post-thrombotic phenomena. However,
to what extent high factor VIII levels are genetically determined is still
unclear. Factor VIII:C levels show a familial clustering, which remains
after correction for blood group and vWF (14), but a molecular basis of
elevated factor VIII levels within the factor VIII gene has not been
found (15,16). The next step will be to analyze whether there is a rela-
tionship between elevated factor VIII levels and familial thrombo-
philia, in order to investigate the heritability of high factor VIII levels
and its influence on the thrombosis risk in families.
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Recent discoveries have established the endothelium äs a very large and
highly active endocrine organ which, through its Strategie Situation be-
tween the blood and the rest of the body, is responsible for a host of vital
physiological functions. This in turn is leading to rapid advances in under-
standing the pathogenesis of some of the most serious and most common
diseases, including hypertension, atherosclerosis, and inflammation. Edi-
tors and authors are internationally leading scientists in these investiga-
tions.
For the endothelium, äs for all other tissues, morphological techniques,
however ingeniously applied, can provide no more than successive snap-
shots of continuous dynamic processes. It is only in more recent years that
these techniques have been supplemented by cell culture in vitro and by
ingenious uses of endothelial mediators in vivo. Nevertheless, many of the
most important questions about endothelial functions remain to be an-
swered. It is the purpose of this book to indicate directions along which
answers may be found.
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